Isis: Three-month diabetes data shows consistent glucose improvement

By Elaine Rigoli

Tampa, Fla., June 13 - Isis Pharmaceuticals, Inc. released positive phase 2 results in patients with type 2 diabetes treated with ISIS 113715 as a single-agent, showing it did not cause hypoglycemia (low blood sugar), did not cause weight gain and was well-tolerated.

The company said that, after three months of treatment, patients treated with 200 mg/week of ISIS 113715 showed consistent improvement from baseline in several indices of blood glucose control.

Reduction in several of these indices was statistically significant as compared to placebo-treated subjects, according to a news release.

The study was divided into two parts, a dose-escalation portion designed primarily to assess the safety of six weeks of dosing with ISIS 113715 at weekly doses of 100, 200, 400 and 600 mg, and a three-month dosing group at 200 mg/week designed to determine the effects of treatment with ISIS 113715 on several measures of blood glucose control.

ISIS 113715, a second-generation antisense drug, is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B, a mediator of insulin resistance, one of two main defects in patients with type 2 diabetes.

Located in Carlsbad, Calif., Isis' drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.